Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 186

1.

Pharmacodynamics of daptomycin when prescribed in combination with other antibiotics for treatment of enterococcal bacteremia.

Avery LM, Kuti JL, Weisser M, Egli A, Rybak MJ, Zasowski EJ, Arias CA, Contreras GA, Chong PP, Aitken SL, DiPippo AJ, Wang JT, Britt NS, Nicolau DP.

Int J Antimicrob Agents. 2019 Jul 5. pii: S0924-8579(19)30182-7. doi: 10.1016/j.ijantimicag.2019.07.002. [Epub ahead of print]

PMID:
31284042
2.

In vitro Activity of Imipenem-Relebactam Alone or in Combination with Amikacin or Colistin against Pseudomonas aeruginosa.

Asempa TE, Nicolau DP, Kuti JL.

Antimicrob Agents Chemother. 2019 Jul 1. pii: AAC.00997-19. doi: 10.1128/AAC.00997-19. [Epub ahead of print]

PMID:
31262769
4.

A Simulated Application of the Hartford Hospital Aminoglycoside Dosing Nomogram for Plazomicin Dosing Interval Selection in Patients With Serious Infections Caused by Carbapenem-Resistant Enterobacterales.

Asempa TE, Kuti JL, Seroogy JD, Komirenko AS, Nicolau DP.

Clin Ther. 2019 May 23. pii: S0149-2918(19)30241-3. doi: 10.1016/j.clinthera.2019.04.038. [Epub ahead of print]

PMID:
31248681
5.

Carbapenem Non-susceptible Pseudomonas aeruginosa from Intensive Care Units in the United States: A Potential Role for New β-lactam Combination Agents.

Asempa TE, Nicolau DP, Kuti JL.

J Clin Microbiol. 2019 May 22. pii: JCM.00535-19. doi: 10.1128/JCM.00535-19. [Epub ahead of print]

PMID:
31118271
6.

In Vitro Pharmacodynamics of a Novel Ceftibuten-Clavulanate Combination Antibiotic against Enterobacteriaceae.

Grupper M, Stainton SM, Nicolau DP, Kuti JL.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00144-19. doi: 10.1128/AAC.00144-19. Print 2019 Jul.

PMID:
31061148
7.

Where should antibiotic gradient diffusion strips be crossed to assess synergy? A comparison of the standard method with a novel method using steady-state antimicrobial concentrations.

Motos A, Avery LM, DeRonde KJ, Mullane EM, Kuti JL, Nicolau DP.

Int J Antimicrob Agents. 2019 May;53(5):698-702. doi: 10.1016/j.ijantimicag.2019.03.006. Epub 2019 Mar 14.

PMID:
30880231
8.

Reply to Cheng and Chuang.

Avery LM, Kuti JL, Weisser M, Egli A, Rybak MJ, Zasowski EJ, Arias CA, Contreras GA, Chong PP, Aitken SL, DiPippo AJ, Wang JT, Britt NS, Nicolau DP.

Clin Infect Dis. 2019 Jan 30. doi: 10.1093/cid/ciz081. [Epub ahead of print] No abstract available.

PMID:
30715199
9.

Patient preferences for treatment of acute bacterial skin and skin structure infections in the emergency department.

Almarzoky Abuhussain SS, Burak MA, Kohman KN, Jacknin G, Tart SB, Hobbs ALV, Adams DK, Nailor MD, Keyloun KR, Nicolau DP, Kuti JL.

BMC Health Serv Res. 2018 Dec 4;18(1):932. doi: 10.1186/s12913-018-3751-0.

10.

Is One Sample Enough? β-Lactam Target Attainment and Penetration into Epithelial Lining Fluid Based on Multiple Bronchoalveolar Lavage Sampling Time Points in a Swine Pneumonia Model.

Motos A, Kuti JL, Li Bassi G, Torres A, Nicolau DP.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01922-18. doi: 10.1128/AAC.01922-18. Print 2019 Feb.

PMID:
30509937
11.

Corrigendum to Physical Compatibility of Meropenem and Vaborbactam with Select Intravenous Drugs During Simulated Y-site Administration [Clinical Therapeutics 40 (2018) 261-269].

Kidd JM, Avery LM, Asempa TE, Nicolau DP, Kuti JL.

Clin Ther. 2018 Nov;40(11):1956. doi: 10.1016/j.clinthera.2018.09.013. Epub 2018 Oct 16. No abstract available.

PMID:
30336952
12.

Variability in Emergency Medicine Provider Decisions on Hospital Admission and Antibiotic Treatment in a Survey Study for Acute Bacterial Skin and Skin Structure Infections: Opportunities for Antimicrobial Stewardship Education.

Almarzoky Abuhussain SS, Burak MA, Adams DK, Kohman KN, Tart SB, Hobbs ALV, Jacknin G, Nailor MD, Keyloun KR, Nicolau DP, Kuti JL.

Open Forum Infect Dis. 2018 Oct 8;5(10):ofy206. doi: 10.1093/ofid/ofy206. eCollection 2018 Oct.

13.

Pharmacodynamic Analysis of Daptomycin-Treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint.

Avery LM, Kuti JL, Weisser M, Egli A, Rybak MJ, Zasowski EJ, Arias CA, Contreras GA, Chong PP, Aitken SL, DiPippo AJ, Wang JT, Britt NS, Nicolau DP.

Clin Infect Dis. 2018 Sep 5. doi: 10.1093/cid/ciy749. [Epub ahead of print]

PMID:
30188976
14.
15.

Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.

Asempa TE, Avery LM, Kidd JM, Kuti JL, Nicolau DP.

Am J Health Syst Pharm. 2018 Jul 15;75(14):1048-1056. doi: 10.2146/ajhp170839. Epub 2018 Jun 12.

PMID:
29895521
16.
17.

Meropenem time above the MIC exposure is predictive of response in cystic fibrosis children with acute pulmonary exacerbations.

Kuti JL, Pettit RS, Neu N, Cies JJ, Lapin C, Muhlebach MS, Novak KJ, Nguyen ST, Saiman L, Nicolau DP.

Diagn Microbiol Infect Dis. 2018 Jul;91(3):294-297. doi: 10.1016/j.diagmicrobio.2018.01.020. Epub 2018 Feb 24.

PMID:
29661528
18.

Efficacy of Human-Simulated Exposures of Ceftolozane-Tazobactam Alone and in Combination with Amikacin or Colistin against Multidrug-Resistant Pseudomonas aeruginosa in an In Vitro Pharmacodynamic Model.

Rico Caballero V, Almarzoky Abuhussain S, Kuti JL, Nicolau DP.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02384-17. doi: 10.1128/AAC.02384-17. Print 2018 May.

19.

Novel pharmacotherapy for the treatment of hospital-acquired and ventilator-associated pneumonia caused by resistant gram-negative bacteria.

Kidd JM, Kuti JL, Nicolau DP.

Expert Opin Pharmacother. 2018 Mar;19(4):397-408. doi: 10.1080/14656566.2018.1438408. Epub 2018 Feb 19. Review.

PMID:
29411661
20.

Physical Compatibility of Meropenem and Vaborbactam With Select Intravenous Drugs During Simulated Y-site Administration.

Kidd JM, Avery LM, Asempa TE, Nicolau DP, Kuti JL.

Clin Ther. 2018 Feb;40(2):261-269. doi: 10.1016/j.clinthera.2017.12.007. Epub 2017 Dec 28. Erratum in: Clin Ther. 2018 Nov;40(11):1956.

PMID:
29290374
21.

Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.

Monogue ML, Almarzoky Abuhussain SS, Kuti JL, Nicolau DP.

Am J Health Syst Pharm. 2018 Jan 1;75(1):e36-e44. doi: 10.2146/ajhp170123.

PMID:
29273611
22.

Simplifying Piperacillin/Tazobactam Dosing: Pharmacodynamics of Utilizing Only 4.5 or 3.375 g Doses for Patients With Normal and Impaired Renal Function.

Thabit AK, Grupper M, Nicolau DP, Kuti JL.

J Pharm Pract. 2017 Dec;30(6):593-599. doi: 10.1177/0897190016684453. Epub 2016 Dec 21.

PMID:
29121839
23.

Comparative Assessment of Tedizolid Pharmacokinetics and Tissue Penetration between Diabetic Patients with Wound Infections and Healthy Volunteers via In Vivo Microdialysis.

Stainton SM, Monogue ML, Baummer-Carr A, Shepard AK, Nugent JF, Kuti JL, Nicolau DP.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01880-17. doi: 10.1128/AAC.01880-17. Print 2018 Jan.

24.

Effects of Clinically Meaningful Concentrations of Antipseudomonal β-Lactams on Time to Detection and Organism Growth in Blood Culture Bottles.

Grupper M, Nicolau DP, Aslanzadeh J, Tanner LK, Kuti JL.

J Clin Microbiol. 2017 Dec;55(12):3502-3512. doi: 10.1128/JCM.01241-17. Epub 2017 Oct 11.

25.

Pharmacokinetics and Tissue Penetration of Ceftolozane-Tazobactam in Diabetic Patients with Lower Limb Infections and Healthy Adult Volunteers.

Monogue ML, Stainton SM, Baummer-Carr A, Shepard AK, Nugent JF, Kuti JL, Nicolau DP.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01449-17. doi: 10.1128/AAC.01449-17. Print 2017 Dec.

26.

Defining the impact of severity of illness on time above the MIC threshold for cefepime in Gram-negative bacteraemia: a 'Goldilocks' window.

Miglis C, Rhodes NJ, Kuti JL, Nicolau DP, Van Wart SA, Scheetz MH.

Int J Antimicrob Agents. 2017 Sep;50(3):487-490. doi: 10.1016/j.ijantimicag.2017.04.023. Epub 2017 Jun 28.

PMID:
28668683
27.

Prevalence, patient characteristics and outcomes of a novel piperacillin/tazobactam-resistant, pan-β-lactam-susceptible phenotype in Enterobacteriaceae: implications for selective reporting.

Stainton SM, Thabit AK, Kuti JL, Aslanzadeh J, Nicolau DP.

Clin Microbiol Infect. 2017 Aug;23(8):581-582. doi: 10.1016/j.cmi.2017.02.012. Epub 2017 Feb 22. No abstract available.

28.

In vitro blood culture bottle inoculation of whole blood with clinically relevant antibiotic concentrations: a word of caution.

Grupper M, Kuti JL, Nicolau DP.

Eur J Clin Microbiol Infect Dis. 2017 May;36(5):917-919. doi: 10.1007/s10096-016-2874-7. Epub 2016 Dec 28. No abstract available.

PMID:
28032283
29.

Physical compatibility of isavuconazonium sulfate with select i.v. drugs during simulated Y-site administration.

So W, Kim L, Thabit AK, Nicolau DP, Kuti JL.

Am J Health Syst Pharm. 2017 Jan 1;74(1):e55-e63. doi: 10.2146/ajhp150733. Epub 2016 Dec 22.

PMID:
28007722
30.

Population Pharmacokinetics of Cefazolin in Serum and Adipose Tissue From Overweight and Obese Women Undergoing Cesarean Delivery.

Grupper M, Kuti JL, Swank ML, Maggio L, Hughes BL, Nicolau DP.

J Clin Pharmacol. 2017 Jun;57(6):712-719. doi: 10.1002/jcph.851. Epub 2016 Dec 7.

PMID:
27925657
31.

Mortality, Hospital Costs, Payments, and Readmissions Associated With Clostridium difficile Infection Among Medicare Beneficiaries.

Drozd EM, Inocencio TJ, Braithwaite S, Jagun D, Shah H, Quon NC, Broderick KC, Kuti JL.

Infect Dis Clin Pract (Baltim Md). 2015 Nov;23(6):318-323. Epub 2015 Nov 2.

32.

Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients.

Minichmayr IK, Schaeftlein A, Kuti JL, Zeitlinger M, Kloft C.

Clin Pharmacokinet. 2017 Jun;56(6):617-633. doi: 10.1007/s40262-016-0463-7.

PMID:
27753002
33.

Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation.

Monogue ML, Pettit RS, Muhlebach M, Cies JJ, Nicolau DP, Kuti JL.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6578-6584. doi: 10.1128/AAC.01566-16. Print 2016 Nov.

34.

Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration.

Kuti JL, Ghazi IM, Quintiliani R Jr, Shore E, Nicolau DP.

Int J Antimicrob Agents. 2016 Sep;48(3):342-3. doi: 10.1016/j.ijantimicag.2016.06.005. Epub 2016 Jul 8. No abstract available.

PMID:
27451086
35.

Continuous and Prolonged Intravenous β-Lactam Dosing: Implications for the Clinical Laboratory.

Grupper M, Kuti JL, Nicolau DP.

Clin Microbiol Rev. 2016 Oct;29(4):759-72. doi: 10.1128/CMR.00022-16. Review.

36.

Stability of Ertapenem 100 mg/mL at Room Temperature.

Kuti JL, Nicolau DP.

Can J Hosp Pharm. 2016 May-Jun;69(3):256-9. Epub 2016 Jun 30. No abstract available.

37.

The Essential Role of Pharmacists in Antimicrobial Stewardship.

Heil EL, Kuti JL, Bearden DT, Gallagher JC.

Infect Control Hosp Epidemiol. 2016 Jul;37(7):753-4. doi: 10.1017/ice.2016.82. Epub 2016 Apr 13. No abstract available.

PMID:
27072411
38.

Tissue penetration and exposure of cefepime in patients with diabetic foot infections.

So W, Kuti JL, Shepard A, Nugent J, Nicolau DP.

Int J Antimicrob Agents. 2016 Mar;47(3):247-8. doi: 10.1016/j.ijantimicag.2016.01.002. Epub 2016 Feb 1. No abstract available.

PMID:
26897754
39.

Antibiotic Utilization and Opportunities for Stewardship Among Hospitalized Patients With Influenza Respiratory Tract Infection.

Ghazi IM, Nicolau DP, Nailor MD, Aslanzadeh J, Ross JW, Kuti JL.

Infect Control Hosp Epidemiol. 2016 May;37(5):583-9. doi: 10.1017/ice.2016.17. Epub 2016 Feb 1.

PMID:
26832841
40.

An exploratory analysis of the ability of a cefepime trough concentration greater than 22 mg/L to predict neurotoxicity.

Rhodes NJ, Kuti JL, Nicolau DP, Neely MN, Nicasio AM, Scheetz MH.

J Infect Chemother. 2016 Feb;22(2):78-83. doi: 10.1016/j.jiac.2015.10.009. Epub 2015 Dec 17.

PMID:
26712584
41.

Optimizing Antibiotic Dosing Strategies for the Treatment of Gram-negative Infections in the Era of Resistance.

Monogue ML, Kuti JL, Nicolau DP.

Expert Rev Clin Pharmacol. 2016;9(3):459-76. doi: 10.1586/17512433.2016.1133286. Epub 2016 Jan 16. Review.

PMID:
26678036
42.

Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival.

Rhodes NJ, Kuti JL, Nicolau DP, Van Wart S, Nicasio AM, Liu J, Lee BJ, Neely MN, Scheetz MH.

Antimicrob Agents Chemother. 2015 Dec 14;60(3):1401-10. doi: 10.1128/AAC.01956-15.

43.

In Vitro Pharmacodynamics of Vancomycin against Methicillin-Susceptible and -Resistant Staphylococcus aureus: Considering the Variability in Observed Tissue Exposure.

Hamada Y, Kuti JL, Nicolau DP.

Antimicrob Agents Chemother. 2015 Nov 30;60(2):955-61. doi: 10.1128/AAC.01553-15. Print 2016 Feb.

44.

Assessment of Clostridium difficile Burden in Patients Over Time With First Episode Infection Following Fidaxomicin or Vancomycin.

Housman ST, Thabit AK, Kuti JL, Quintiliani R, Nicolau DP.

Infect Control Hosp Epidemiol. 2016 Feb;37(2):215-8. doi: 10.1017/ice.2015.270. Epub 2015 Nov 23.

PMID:
26592763
45.

Pharmacokinetic/pharmacodynamic target attainment of intravenous β-lactam regimens against Gram-negative bacteria isolated in a Brazilian teaching hospital.

Furtado GH, Cardinal L, Macedo RS, Silva JO, Medeiros EA, Kuti JL, Nicolau DP.

Rev Soc Bras Med Trop. 2015 Sep-Oct;48(5):539-45. doi: 10.1590/0037-8682-0122-2015.

46.

In Vitro Pharmacodynamics of Human Simulated Exposures of Telavancin against Methicillin-Susceptible and -Resistant Staphylococcus aureus with and without Prior Vancomycin Exposure.

Thabit AK, Nicolau DP, Kuti JL.

Antimicrob Agents Chemother. 2015 Oct 19;60(1):222-8. doi: 10.1128/AAC.02033-15. Print 2016 Jan.

47.

Population pharmacokinetics of meropenem administered as a prolonged infusion in children with cystic fibrosis.

Pettit RS, Neu N, Cies JJ, Lapin C, Muhlebach MS, Novak KJ, Nguyen ST, Saiman L, Nicolau DP, Kuti JL.

J Antimicrob Chemother. 2016 Jan;71(1):189-95. doi: 10.1093/jac/dkv289. Epub 2015 Sep 27.

PMID:
26416780
48.

Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis.

Kuti JL, Pettit RS, Neu N, Cies JJ, Lapin C, Muhlebach MS, Novak KJ, Nguyen ST, Saiman L, Nicolau DP.

Diagn Microbiol Infect Dis. 2015 Sep;83(1):53-5. doi: 10.1016/j.diagmicrobio.2015.04.012. Epub 2015 May 1.

PMID:
26003469
49.

Vancomycin serum concentrations do not adequately predict tissue exposure in diabetic patients with mild to moderate limb infections.

Hamada Y, Kuti JL, Nicolau DP.

J Antimicrob Chemother. 2015 Jul;70(7):2064-7. doi: 10.1093/jac/dkv074. Epub 2015 Mar 22.

PMID:
25802284
50.

Presence of infection influences the epithelial lining fluid penetration of oral levofloxacin in adult patients.

Kuti JL, Nicolau DP.

Int J Antimicrob Agents. 2015 May;45(5):512-8. doi: 10.1016/j.ijantimicag.2014.12.028. Epub 2015 Feb 11.

PMID:
25726443

Supplemental Content

Support Center